William D. Waddill, Director at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 16,234 shares at $68.01 ($1.1M) on 2025-12-19, disclosed to the SEC on 2025-12-23.
Scheduled sale ($1.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.66 | 2,416 | $161K | 14.7% |
| 2 | $66.66 | 2,416 | $161K | 14.7% |
| 3 | $68.01 | 5,451 | $371K | 33.8% |
| 4 | $68.01 | 5,451 | $371K | 33.8% |
| 5 | $68.53 | 500 | $34K | 3.1% |
| Total | $67.62 avg | 16,234 |
| $1.1M |
| 100% |
| Filing → |
| PTGX | SELL | 2026-06-01 | $897K | — | Filing → |
| PTGX | SELL | 2026-02-06 | $1.7M | — | Filing → |
| PTGX | SELL | 2025-10-14 | $979K | — | Filing → |